本文選題：CXCR7 + 宮頸癌　； 參考：《遼寧中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的:探究趨化因子受體7(CXCR7)沉默對(duì)He La細(xì)胞侵襲及遷移能力的影響及其在宮頸癌組織中的表達(dá)意義,為宮頸癌侵襲轉(zhuǎn)移機(jī)制提供理論證據(jù),為尋找宮頸癌生物學(xué)指標(biāo)及治療的特異性靶分子開拓新思路;探究中藥康艾與胸腺五肽對(duì)宮頸癌患者T淋巴細(xì)胞亞群的影響。材料與方法:1.研究20例宮頸癌組織及5例正常宮頸組織標(biāo)本均來(lái)自遼寧省腫瘤醫(yī)院,宮頸癌組織標(biāo)本均經(jīng)病理組織學(xué)證實(shí)。利用免疫組織化學(xué)檢測(cè)CXCR7在宮頸癌組織及正常宮頸組織中的表達(dá)情況。人宮頸癌細(xì)胞系He La細(xì)胞為實(shí)驗(yàn)室液氮常規(guī)儲(chǔ)藏。靶向CXCR7的sh RNA質(zhì)粒(CXCR7-sh RNA)或?qū)φ召|(zhì)粒(Ctrl-sh RNA)轉(zhuǎn)染He La細(xì)胞后,通過(guò)Transwell小室法檢測(cè)細(xì)胞侵襲和遷移能力變化。2.選取2014-2016于遼寧省腫瘤醫(yī)院婦科住院的宮頸癌根治術(shù)后放化療后結(jié)束后3-6個(gè)月患者30例,隨機(jī)將其分為2組,每組各15例,分別給予康艾注射液和胸腺五肽進(jìn)行免疫治療,10日為一療程,治療1療程后,觀察其外周血T淋巴細(xì)胞亞群較治療前變化情況。結(jié)果:1.CXCR7蛋白在宮頸癌組織中均呈陽(yáng)性表達(dá),且在正常宮頸組織中呈陰性表達(dá)。2.Transwell侵襲和遷移實(shí)驗(yàn)中CXCR7-sh RNA轉(zhuǎn)染組He La細(xì)胞穿過(guò)基質(zhì)膠和基底膜的數(shù)量顯著低于陰性對(duì)照質(zhì)粒轉(zhuǎn)染組及未處理組。3.康艾組治療后患者外周血T淋巴細(xì)胞亞群中CD3+、CD4+、CD8+測(cè)定值較治療前均升高,CD4+/CD8+和NK值降低,且均具有統(tǒng)計(jì)學(xué)意義(P0.05)。胸腺五肽組治療后,患者T淋巴細(xì)胞亞群CD4+、CD4+/CD8+及NK測(cè)定值較治療前均升高,CD3+、CD8+測(cè)定值降低,且具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:1.宮頸癌組織中特異性高表達(dá)CXCR7,將有望成為宮頸癌早期診斷、預(yù)后判斷及靶向治療的新靶點(diǎn)。2.抑制He La細(xì)胞中CXCR7蛋白表達(dá)可顯著抑制其侵襲遷移能力,為宮頸癌侵襲轉(zhuǎn)移機(jī)制提供新的理論依據(jù)。3.中藥康艾與胸腺五肽均可影響宮頸癌術(shù)后放化療后患者外周血T淋巴細(xì)胞亞群,改善并提高患者的免疫能力,提高患者生活質(zhì)量。
[Abstract]:Aim: to investigate the effect of chemokine receptor 7 (CXCR7) silencing on the invasion and migration of He-La cells and its expression in cervical carcinoma, and to provide theoretical evidence for the mechanism of invasion and metastasis of cervical cancer. In order to find out the biological indexes and specific target molecules for treatment of cervical cancer and explore the effect of Chinese medicine Kangai and thymus pentapeptide on T lymphocyte subsets in patients with cervical cancer. Materials and methods: 1. The specimens of 20 cases of cervical carcinoma and 5 cases of normal cervical tissues were all from Liaoning Provincial Cancer Hospital. The specimens of cervical carcinoma were confirmed by histopathology. Immunohistochemistry was used to detect the expression of CXCR7 in cervical carcinoma and normal cervix. Human cervical cancer cell line he La was stored in laboratory with liquid nitrogen. He-La cells were transfected with sh RNA targeting CXCR7 (CXCR7-sh RNAs) or Ctrl-sh RNAs (control plasmid Ctrl-sh RNAs). Cell invasion and migration were detected by Transwell chamber assay. Thirty patients with cervical cancer hospitalized in gynecological department of Liaoning Provincial Oncology Hospital from 2014 to 2016 were randomly divided into two groups, 15 cases in each group, 3 to 6 months after radiotherapy and chemotherapy. Kangai injection and thymus pentapeptide were given immunotherapy for 10 days. After one course of treatment, the changes of T lymphocyte subsets in peripheral blood were observed. Results: 1. The expression of CXCR7 protein was positive in cervical carcinoma. The number of He-La cells passing through matrix glue and basement membrane in CXCR7-sh RNA transfection group was significantly lower than that in negative control plasmid transfection group and untreated group. 2. The number of He-La cells passing through matrix glue and basement membrane in CXCR7-sh RNA transfection group was significantly lower than that in negative control plasmid transfection group and untreated group. In Kangai group, the levels of CD3 T lymphocyte subsets in T lymphocyte subsets were significantly higher than those before treatment, and the levels of CD 4 / CD 8 and NK were significantly lower than those before treatment (P 0.05). In the thymopeptide group, the T lymphocyte subsets (CD4, CD 4 / CD 8 and NK) were higher than those before treatment, and the CD3 / CD 8 levels were significantly lower than those before treatment, and there was a statistically significant difference between the two groups (P 0.05). Conclusion 1. The specific overexpression of CXCR7 in cervical carcinoma will be a new target for early diagnosis, prognosis judgment and targeted therapy of cervical cancer. Inhibiting the expression of CXCR7 protein in He-La cells can significantly inhibit its ability of invasion and migration, and provide a new theoretical basis for the mechanism of invasion and metastasis of cervical cancer. Both Kangai and thymus pentapeptide can affect the T lymphocyte subsets of peripheral blood of patients with cervical cancer after radiotherapy and chemotherapy, improve and improve the immune ability of patients, improve the quality of life of patients.
【學(xué)位授予單位】：遼寧中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李欽;胡繼宏;高博;李海東;宋爽;楊麗霞;;黃芪多糖在免疫調(diào)節(jié)方面的最新研究進(jìn)展[J];中國(guó)實(shí)驗(yàn)方劑學(xué)雜志;2017年02期

2 羅旭瑋;趙凱;郭青龍;;CXCR7的生物學(xué)功能及其在腫瘤發(fā)生發(fā)展中的作用研究進(jìn)展[J];藥學(xué)進(jìn)展;2016年09期

3 陳振棟;張佳;劉振平;趙云波;胡明;;SDF1、CXCR7在胃癌中的表達(dá)及意義[J];黑龍江醫(yī)藥科學(xué);2016年01期

4 高卓維;曾少容;黃景彬;喬冠英;;康艾注射液對(duì)鼻咽癌患者外周血T細(xì)胞亞群的影響[J];中醫(yī)研究;2015年07期

5 程璐;李林;謝旭;;分子靶向藥物治療宮頸癌研究進(jìn)展[J];實(shí)用藥物與臨床;2015年05期

6 喬友林;趙宇倩;;宮頸癌的流行病學(xué)現(xiàn)狀和預(yù)防[J];中華婦幼臨床醫(yī)學(xué)雜志(電子版);2015年02期

7 高純子;韓波;李瑛;林珊;楊麗姝;;放化療對(duì)惡性腫瘤患者T細(xì)胞亞群的影響[J];中國(guó)腫瘤臨床與康復(fù);2014年11期

8 武彥佼;薛曉英;劉春梅;李彥格;;宮頸癌放療的研究進(jìn)展[J];河北醫(yī)藥;2014年21期

9 曹園芝;楊飛華;馬偉峰;;CXCR7與腫瘤的生長(zhǎng)和轉(zhuǎn)移[J];中國(guó)腫瘤生物治療雜志;2014年02期

10 朱秀軍;鄭素琴;;趨化因子受體CXCR7在婦科腫瘤中的研究進(jìn)展[J];中國(guó)當(dāng)代醫(yī)藥;2014年08期

，

本文編號(hào)：1973073